Sign In
Buy PLX
$1.96
-0.0300 (-1.51%)
At Close: Jun 03, 2026
Protalix BioTherapeutics lifts revenue on strong Elfabrio demand
08:39am, Thursday, 14'th Aug 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported higher quarterly revenue and reaffirmed its long-term growth outlook on Thursday, pointing to expanding demand for its Fabry disease treatment Elfabr
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
06:50am, Thursday, 14'th Aug 2025
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company foc
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
12:53pm, Thursday, 07'th Aug 2025
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on
Protalix BioTherapeutics welcomes new finance chief
09:09am, Monday, 21'st Jul 2025
Protalix BioTherapeutics Inc (NYSE-A:PLX) has announced the appointment of Gilad Mamlok as senior vice president and chief financial officer, succeeding Eyal Rubin. Mamlok has already joined the compa
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
06:50am, Monday, 21'st Jul 2025
CARMIEL, Israel , July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recom
Protalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitution
08:47am, Monday, 30'th Jun 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has been added to the Russell 3000 and Russell 2000 Indexes, effective after the US market closed on Friday, June 27. The inclusion follo
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
06:50am, Monday, 30'th Jun 2025
CARMIEL, Israel , June 30, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recomb
Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript
04:12pm, Friday, 09'th May 2025
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Moyer – Investor Relations Dror Bashan – President and Chief Executive
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth
08:41am, Friday, 09'th May 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout treatment PRX-115 later this year, as the company builds on momentum from pos
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
06:50am, Friday, 09'th May 2025
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focus
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline
09:54am, Thursday, 10'th Apr 2025
Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119. Elelyso and Elfabrio provide recurring revenue, with incre
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI
12:56pm, Friday, 21'st Mar 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explai
Protalix Biotherapeutics gains momentum: analysts see long-term upside
02:51pm, Tuesday, 18'th Mar 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's i
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate
08:51am, Tuesday, 18'th Mar 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline,
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
11:56am, Monday, 17'th Mar 2025
On Monday, Protalix BioTherapeutics, Inc. PLX reported fiscal 2024 earnings of 4 cents, beating the consensus of 1 cent.
